Ipratropium Bromide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ipratropium Bromide 是 M3 型毒蕈碱乙酰胆碱受体的拮抗剂，用于治疗慢性阻塞性肺疾病 (COPD)。

Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).

Cell Viability Assay Cell Line:Adult Rat Cardiac Myocyte Concentration:0.001 nM-0.1 mM Incubation Time:2 h in dark; prior to 4 h hypoxia Result:Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose.

Animal Model:Guinea-pigs of the Dunkin Hartley strain.Dosage:0.1-1 μg/kg Administration:Intravenous injection; single dose Result:Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg.Animal Model:Male Sprague-Dawley rats (300-350 g) Dosage:0.04 mg/20 mL and 0.20 mg/20 mL Administration:Inhalation; atomization rate of 30 mL/30 min; 30 min Result:Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium.

Ipratropium Bromide

Endocrinology/Hormones

AChR

M3 mAChR

Neurological Disease

——

22254-24-6

412.37

C20H30BrNO3

>98% (HPLC)

DMSO:83 mg/mL (201.27 mM); Ethanol:83 mg/mL (201.27 mM); Water:83 mg/mL (201.27 mM)

CC([N+]1(C)C2CC(OC(C(C3=CC=CC=C3)CO)=O)CC1CC2)C.[Br-]

(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide

(-20℃)

With Ice Pack

≥ 2 years